Galectin Therapeutics has appointed Henry Brem, M.D., as an independent director to its Board. Brem serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center. Brem’s experience developing image-guided techniques and Gliadel® wafers for brain tumors will bolster Galectin’s belapectin clinical programs in MASH cirrhosis and portal hypertension as the company advances toward regulatory milestones. Brem is an internationally recognized neurosurgeon-scientist with over four decades of continuous NIH funding, 416 peer-reviewed papers, multiple patents and membership in the National Academy of Medicine, highlighting his translational research leadership.